Rapport Therapeutics, Inc.

RAPP

Rapport Therapeutics, Inc.

RAPP

Insider Sentiment (TTM):

Last Purchase:2025-09-12Last Sale:2026-05-26Shares Purchased (TTM):65,566Shares Sold (TTM):776,534

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:50,955,456Shares Outstanding:47,236,618Institutional Ownership Pct.:107.87%

Earnings Market Reaction:

Filing Date:2026-08-05Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	64	78	53	251	55	58	57	39	110
Accounts Receivable Net Current	0	0	-	-	-	-	-	-	-
Short Term Investments	372	399	438	262	205	228	248	281	226
Restricted Cash Current	0	0	0	0	0	0	0	0	0
Prepaid Expense And Other Assets Current	10	8	8	8	10	5	4	5	4
Assets Current	447	485	499	521	270	291	310	326	341
Property Plant And Equipment Net	2	3	3	3	3	3	4	3	3
Operating Lease Right Of Use Asset	9	9	10	10	11	7	1	2	2
Other Assets Noncurrent	1	1	1	1	1	0	0	0	0
Assets	459	498	512	535	285	302	315	331	346
Liabilities And Stockhold…
Liabilities Current
Accounts Payable Current	3	7	4	3	3	2	2	1	2
Accrued Liabilities Current	23	9	12	9	7	6	6	5	6
Operating Lease Liability Current	2	3	3	2	2	1	1	1	1
Liabilities Current	28	18	19	14	12	9	9	7	8
Operating Lease Liability Noncurrent	8	8	9	9	10	7	1	1	1
Liabilities	36	26	28	24	22	16	10	8	9
Stockholders Equity
Preferred Stock Value	0	0	0	0	0	-	0	-	0
Common Stock Value	0	0	0	0	0	0	0	0	0
Additional Paid In Capital Common Stock	736	727	719	713	438	434	430	426	423
Accumulated Other Comprehensive Income Loss Net Of…	-1	-1	1	0	-0	-0	-1	0	-0
Retained Earnings Accumulated Deficit	-312	-255	-235	-201	-175	-148	-124	-104	-86
Stockholders Equity	423	472	485	512	264	286	305	323	-337
Liabilities And Stockholders Equity	459	498	512	535	285	302	315	331	346
Series A Convertible Preferred Stock	-	-	-	-	-	-	0	-0	0
Series B Convertible Preferred Stock	-	-	-	-	-	-	0	-22	22
Third Rock Ventures L L C	-	-	-	0	0	-	0	0	0
Maximum	-	-	0	-	-	-	0	0	0
Minimum	-	-	0	0	0	0	0	0	0
Preferred Stock Par Or Stated Value Per Share	0.001	0.001	0.001	0.001	0.001	-	0.001	-	0.001
Preferred Stock Shares Authorized	10	10	10	10	10	-	10	-	10
Preferred Stock Shares Issued	0	0	0	0	0	-	0	-	0
Preferred Stock Shares Outstanding	0	0	0	0	0	-	0	-	0
Common Stock Par Or Stated Value Per Share	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001
Common Stock Shares Authorized	500	500	500	500	500	500	500	500	500
Common Stock Shares Issued	48	48	48	48	36	36	37	37	37
Shares Outstanding	48	48	48	48	36	36	37	37	37

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	-1.08%	0.33%	1.88%	-	-	-	-	-	-	-	-	-
2025	-22.35%	7.32%	50.70%	14.41%	72.55%	68.27%	17.15%	19.09%	6.19%	13.33%	14.38%	33.31%
2024	-	-	-	17.19%	14.92%	30.50%	-15.09%	-29.26%	-48.33%	0.33%	26.45%	-7.70%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30
Liquidity Ratios
Current Ratio	15.72	27.08	26.17	36.37	22.75	31.01	35.34	45.91	42.08
Quick Ratio	15.36	26.65	25.76	35.84	21.93	30.43	34.83	45.18	41.54
Working Capital	418.43M	466.80M	479.51M	506.34M	258.36M	281.59M	301.04M	318.84M	332.57M
Leverage & Debt
Debt to Equity	0.09	0.06	0.06	0.05	0.08	0.06	0.03	0.02	-0.03
Debt Ratio	0.08	0.05	0.05	0.04	0.08	0.05	0.03	0.02	0.03
Efficiency & Turnover
Asset Turnover TTM	0.05	0.05	0.00	0.00	0.00	0.00	-	-	-
Days Sales Outstanding TTM	5.35	1.06	-	-	-	-	-	-	-
Receivables Turnover TTM	68.26	344.83	-	-	-	-	-	-	-
Per Share Metrics
Diluted EPS TTM	-2.89	-2.27	-2.86	-3.17	-3.13	-2.90	-	-	-
Free Cash Flow Per Share TTM	-2.20	-1.72	-2.28	-1.53	-1.60	-2.49	-	-	-
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	-	-	-
Margin Metrics
Operating Profit Margin TTM	-767.58%	-611.03%	-	-	-	-	-	-	-
Net Profit Margin TTM	-685.80%	-536.39%	-	-	-	-	-	-	-
Growth Metrics
Net Income Growth (1Y)	23.59%	4.79%	-	-	-	-	-	-	-
EPS Growth (1Y)	-7.73%	-21.76%	-	-	-	-	-	-	-
Valuation Metrics
P/E TTM	-14.42	-13.78	-10.60	-9.36	-3.63	-3.46	-	-	-
P/B TTM	4.68	3.13	2.44	2.20	1.53	1.24	1.20	2.21	-0.74
P/S TTM	98.91	73.90	-	-	-	-	-	-	-
Market Cap	1.98B	1.48B	1.18B	1.13B	403.01M	353.72M	367.90M	713.85M	248.10M
Enterprise Value	1.91B	1.40B	1.13B	875.20M	347.94M	296.12M	311.09M	674.53M	137.94M
Calculated Values
Free Cash Flow TTM	-104.55M	-81.25M	-88.63M	-57.90M	-56.86M	-87.76M	-	-	-
Net Debt	-63.61M	-78.06M	-52.65M	-251.36M	-55.07M	-57.60M	-56.81M	-39.31M	-110.16M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
PEG Ratio
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
EV Revenue TTM
EV FCF TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-05-26Sale

Owner: Third, Rock Ventures V, L…

Title: -

Shares: 18,572

Price/Share: $40.05

Value: $743,808.60

Shares Owned: 6,280,525

Relationship: TenPercentOwner

Ownership: Direct

2026-05-11Sale

Owner: Third, Rock Ventures V, L…

Title: -

Shares: 133,618

Price/Share: $40.24

Value: $5,376,788.32

Shares Owned: 6,299,097

Relationship: TenPercentOwner

Ownership: Direct

2026-05-08Sale

Owner: Third, Rock Ventures Vi, …

Title: -

Shares: 5,018

Price/Share: $40.31

Value: $202,275.58

Shares Owned: 6,432,715

Relationship: TenPercentOwner

Ownership: Direct

2026-04-17Sale

Owner: Yeleswaram, Krishnaswamy

Title: Chief Development Officer

Shares: 20,225

Price/Share: $39.99

Value: $808,797.75

Shares Owned: 246,426

Relationship: Officer

Ownership: Direct

2026-04-17Sale

Owner: Third, Rock Ventures Vi, …

Title: -

Shares: 426,005

Price/Share: $40.32

Value: $17,176,521.60

Shares Owned: 6,709,228

Relationship: TenPercentOwner

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-05-26	Third, Rock Ventures V, L…	TenPercentOwner	-	Direct	Sale	18,572	40.05	$743,808.60	6,280,525	4
2026-05-11	Third, Rock Ventures V, L…	TenPercentOwner	-	Direct	Sale	133,618	40.24	$5,376,788.32	6,299,097	4
2026-05-08	Third, Rock Ventures Vi, …	TenPercentOwner	-	Direct	Sale	5,018	40.31	$202,275.58	6,432,715	4
2026-04-17	Yeleswaram, Krishnaswamy	Officer	Chief Development Officer	Direct	Sale	20,225	39.99	$808,797.75	246,426	4
2026-04-17	Third, Rock Ventures Vi, …	TenPercentOwner	-	Direct	Sale	426,005	40.32	$17,176,521.60	6,709,228	4
2026-04-14	Yeleswaram, Krishnaswamy	Officer	Chief Development Officer	Direct	Sale	10,200	35.08	$357,816.00	266,651	4
2026-04-08	Yeleswaram, Krishnaswamy	Officer	Chief Development Officer	Direct	Sale	360	34.90	$12,564.00	286,516	4
2026-03-30	Gault, Cheryl	Officer	Chief Operating Officer	Direct	Sale	10,000	28.30	$283,000.00	159,914	4
2026-03-25	Yeleswaram, Krishnaswamy	Officer	Chief Development Officer	Direct	Sale	10,115	29.99	$303,348.85	286,876	4
2026-03-05	Gault, Cheryl	Officer	Chief Operating Officer	Direct	Sale	2,014	28.93	$58,265.02	169,914	4
2026-02-18	Ceesay, Abraham	Director,Officer	Chief Executive Officer	Direct	Sale	5,833	29.42	$171,606.86	556,247	4
2026-02-17	Bredt, David	Officer	Chief Scientific Officer	Direct	Sale	8,500	28.85	$245,225.00	387,075	4
2026-01-20	Ceesay, Abraham	Director,Officer	Chief Executive Officer	Direct	Sale	5,833	26.12	$152,357.96	562,080	4
2026-01-15	Bredt, David	Officer	Chief Scientific Officer	Direct	Sale	8,500	27.12	$230,520.00	395,575	4
2025-12-31	Bredt, David	Officer	Chief Scientific Officer	Direct	Sale	6,567	30.05	$197,338.35	404,075	4
2025-12-31	Yeleswaram, Krishnaswamy	Officer	Chief Development Officer	Direct	Sale	2,840	30.05	$85,342.00	296,991	4
2025-12-17	Ceesay, Abraham	Director,Officer	Chief Executive Officer	Direct	Sale	5,833	29.97	$174,815.01	567,913	4
2025-12-15	Bredt, David	Officer	Chief Scientific Officer	Direct	Sale	8,500	30.32	$257,720.00	392,642	4
2025-11-26	Gault, Cheryl	Officer	Chief Operating Officer	Direct	Sale	5,000	30.10	$150,500.00	171,928	4
2025-11-17	Bredt, David	Officer	Chief Scientific Officer	Direct	Sale	8,500	25.12	$213,520.00	401,142	4
2025-11-17	Ceesay, Abraham	Director,Officer	Chief Executive Officer	Direct	Sale	5,833	25.18	$146,874.94	573,746	4
2025-10-15	Bredt, David	Officer	Chief Scientific Officer	Direct	Sale	8,500	25.94	$220,490.00	409,642	4
2025-10-15	Ceesay, Abraham	Director,Officer	Chief Executive Officer	Direct	Sale	5,833	25.93	$151,249.69	579,579	4
2025-09-17	Ceesay, Abraham	Director,Officer	Chief Executive Officer	Direct	Sale	40,835	26.58	$1,085,394.30	585,412	4
2025-09-15	Bredt, David	Officer	Chief Scientific Officer	Direct	Sale	8,500	24.27	$206,295.00	418,142	4
2025-09-12	Huber, Reid M	Director	-	Direct	Purchase	20,400	24.48	$499,392.00	20,400	4
2025-09-12	Paul, Steven M	Director	-	Indirect	Purchase	41,666	24.74	$1,030,816.84	41,666	4
2025-09-11	Young, Wendy B.	Director	-	Direct	Purchase	3,500	22.60	$79,100.00	9,500	4
2025-09-08	Gault, Cheryl	Officer	Chief Operating Officer	Direct	Sale	5,000	38.33	$191,650.00	171,928	4
2025-08-15	Bredt, David	Officer	Chief Scientific Officer	Direct	Sale	8,500	15.38	$130,730.00	426,642	4
2025-07-15	Bredt, David	Officer	Chief Scientific Officer	Direct	Sale	8,500	14.00	$119,000.00	435,142	4
2025-06-16	Bredt, David	Officer	Chief Scientific Officer	Direct	Sale	8,500	11.00	$93,500.00	443,642	4
2025-05-15	Bredt, David	Officer	Chief Scientific Officer	Direct	Sale	8,500	9.56	$81,260.00	452,142	4
2025-04-15	Bredt, David	Officer	Chief Scientific Officer	Direct	Sale	8,500	9.57	$81,345.00	460,642	4
2025-03-14	Bredt, David	Officer	Chief Scientific Officer	Direct	Sale	8,500	10.85	$92,225.00	469,142	4
2025-03-13	Ignelzi, Troy A.	Officer	Chief Financial Officer	Direct	Purchase	100	9.98	$998.00	10,000	4
2025-03-12	Young, Wendy B.	Director	-	Direct	Purchase	6,000	10.21	$61,260.00	6,000	4
2024-07-01	Healy, James	Director	-	Indirect	Purchase	44,032	24.59	$1,082,746.88	40,851	4
2024-06-10	Healy, James	Director	-	Indirect	Purchase	558,824	17.00	$9,500,008.00	1,863,327	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

107.87%

Inst. Shares: 50,955,456

Shares Outstanding: 47,236,618

2025-12-31

127.17%

Inst. Shares: 49,514,838

Shares Outstanding: 38,934,569

2025-09-30

125.04%

Inst. Shares: 47,430,848

Shares Outstanding: 37,931,170

2025-06-30

102.36%

Inst. Shares: 36,281,018

Shares Outstanding: 35,444,635

2025-03-31

100.41%

Inst. Shares: 35,411,425

Shares Outstanding: 35,266,577

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	50,955,456	47,236,618	107.87%
2025-12-31	49,514,838	38,934,569	127.17%
2025-09-30	47,430,848	37,931,170	125.04%
2025-06-30	36,281,018	35,444,635	102.36%
2025-03-31	35,411,425	35,266,577	100.41%
2024-12-31	33,775,890	20,738,338	162.87%
2024-09-30	25,584,201	34,855,907	73.40%
2024-06-30	22,447,356	10,666,528	210.45%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

Rapport Therapeutics, Inc. (RAPP) — SEC Financial Statements & Analysis

Rapport Therapeutics, Inc. (RAPP) is a pharmaceutical preparations company, incorporated in DE. Rapport Therapeutics, Inc. trades on Nasdaq as: RAPP. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), Rapport Therapeutics, Inc. reported a Debt-to-Equity ratio of 0.09x, a Price-to-Sales (P/S) ratio of 98.91x (TTM), a Price-to-Book (P/B) ratio of 4.68x (TTM), at a market cap of $1.98B. Figures below are sourced from SEC EDGAR, as-filed.

Debt To Equity: 0.09x
P/S TTM: 98.91x
P/B TTM: 4.68x
Market Cap: $1.98B

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Rapport Therapeutics, Inc. in?

Rapport Therapeutics, Inc. (RAPP) operates in the Pharmaceutical Preparations industry.

What is RAPP's market cap?

Rapport Therapeutics, Inc. (RAPP) has a market capitalization of $1.98B as of 2026-06-30.

What exchange does RAPP trade on?

Rapport Therapeutics, Inc. (RAPP) trades on the Nasdaq.

Where is Rapport Therapeutics, Inc. incorporated?

Rapport Therapeutics, Inc. is incorporated in DE.